Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Jevtana
Cabazitaxel is a semi-synthetic taxane antineoplastic agent used in the treatment of metastatic castration-resistant prostate cancer. It works by disrupting the microtubule network within cells, which is essential for cell division and other cellular functions. It belongs to the taxane class of chemotherapeutic agents.
For the treatment of metastatic castration-resistant prostate cancer.
Severe hypersensitivity reactions, including anaphylaxis, have occurred. Severe hematologic toxicity, including febrile neutropenia, neutropenic sepsis and infections, has occurred. Severe diarrhea, including fatal outcomes, has been reported.
Outcome:
Increased cabazitaxel exposure and toxicity.
Mechanism:
Inhibition of cabazitaxel metabolism.
Outcome:
Altered warfarin metabolism.
Mechanism:
CYP2C9 inhibition.
Outcome:
Reduced cabazitaxel absorption.
Mechanism:
Chelation or altered gastric pH.
Most likely new formulation: Nanoparticle delivery system (Year 2026, 80% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of cabazitaxel being approved for use in other cancer types within the next 5 years.
Antineoplastic Agent, Taxane
Taxane